Cyclooxygenase-2 Induced the β-Amyloid Protein Deposition and Neuronal Apoptosis Via Upregulating the Synthesis of Prostaglandin E2 and 15-Deoxy-Δ12,14-prostaglandin J2.

Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics
Pei-Pei GuanPu Wang

Abstract

Elevated levels of cyclooxygenase-2 (COX-2) and prostaglandins (PGs) have been shown to be involved in the pathogenesis of Alzheimer's disease. Analysis of the underlying mechanisms elucidated a function of sequential PGE2 and PGD2 synthesis in regulating β-amyloid protein (Aβ) deposition by modulating tumor necrosis factor α (TNF-α)-dependent presenilin (PS)1/2 activity in COX-2 and APP/PS1 crossed mice. Specifically, COX-2 overexpression accelerates the expression of microsomal PGE synthase-1 (mPGES-1) and lipocalin-type prostaglandin D synthase (L-PGDS), leading to the synthesis of PGE2 and 15-deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2) in 6-month-old APP/PS1 mice. Consequently, PGE2 has the ability to increase Aβ production by enhancing the expression of PS1/2 in a TNF-α-dependent manner, which accelerates the cognitive decline of COX-2/APP/PS1 mice. More interestingly, low concentrations of 15d-PGJ2 treatment facilitate the effects of PGE2 on the deposition of Aβ via TNF-α-dependent PS1/2 mechanisms. In contrast, high concentrations of 15d-PGJ2 treatment inhibit the deposition of Aβ via suppressing the expression of TNF-α-dependent PS1/2. In this regard, a high concentration of 15d-PGJ2 appears to be a therapeutic agent again...Continue Reading

References

Jan 5, 1999·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·I BlaskoB Grubeck-Loebenstein
Apr 14, 1999·Proceedings of the National Academy of Sciences of the United States of America·T V PetrovaL J Van Eldik
Oct 26, 1999·Neurology·T J MontineJ D Morrow
Feb 22, 2001·Biochemical and Biophysical Research Communications·K KadoyamaT Yoshimoto
Jan 5, 2002·Neurobiology of Aging·A V Yermakova, M K O'Banion
Mar 28, 2002·Learning & Memory·Lisa A TeatherNicolas G Bazan
May 29, 2002·Proceedings of the National Academy of Sciences of the United States of America·Mitsuhiro KondoKoji Uchida
Sep 13, 2002·Brain Research. Molecular Brain Research·Stephanos KyrkanidesM Kerry O'Banion
Jul 25, 2003·Biochemical and Biophysical Research Communications·H S HongI Mook-Jung
Jul 29, 2004·Neuroepidemiology·Christine A SzekelySteven N Goodman
Jul 31, 2004·American Journal of Physiology. Regulatory, Integrative and Comparative Physiology·Alejandro Vazquez-TelloSylvain Chemtob
Oct 2, 2004·American Journal of Physiology. Gastrointestinal and Liver Physiology·Yoko ShinjiChoitsu Sakamoto
Feb 3, 2005·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Takashi MoriharaGreg M Cole
Sep 30, 2005·Toxicology·Seong-Ho KohSeung Hyun Kim
Oct 18, 2006·Journal of Leukocyte Biology·Hilary SandigIan Sabroe
Apr 4, 2007·Proceedings of the National Academy of Sciences of the United States of America·Takahisa KanekiyoYoshihiro Urade
Sep 4, 2007·The Journal of Biological Chemistry·Tatsuya HoshinoTohru Mizushima
May 2, 2009·The Journal of Biological Chemistry·Tatsuya HoshinoTohru Mizushima
Jan 12, 2010·Journal of Alzheimer's Disease : JAD·M Paul Murphy, Harry LeVine
Aug 21, 2010·Frontiers in Aging Neuroscience·Bruno P ImbimboFrancesco Panza

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Methods Mentioned

BETA
enzyme-linked
Assay
ELISA
transgenic
dissection
protein assay
confocal microscopy
genotyping

Software Mentioned

Prism Stat
GraphPad

Related Concepts

Related Feeds

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.